Comparison of 30-day Morbidity and Mortality in Cancer Patients Based on Emergency Department Location
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 13, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The COVER study is focusing on understanding how the location of the emergency department (ED) affects the health outcomes of cancer patients. It aims to find out if being treated in a specialized cancer ED, where doctors have more experience with cancer-related issues, leads to better results for patients compared to visiting a regular ED. This is important because many patients may not have easy access to their cancer care center and might need to visit a different emergency department instead.
To participate in this study, patients must be 18 years or older and have been admitted to an emergency department due to cancer that is either active or in remission for less than a year. If you join the study, researchers will monitor your health outcomes over 30 days after your emergency visit to see how the location of care influences your recovery. The study is not yet recruiting participants, but it aims to improve the understanding of how emergency care location can impact patients with cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 or over admitted to an emergency department with cancer that has been active or in remission for less than a year.
- Exclusion Criteria:
- • - Opposition to participate in the study
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported